Study On The Antidepressant Drugs Based On The Patent Analysis

With the accelerated pace of life and the increase of social pressure, people’s psychological endurance has decreased and depression has become the world’s second major diseases (after cardiovascular disease). Antidepressant drugs have become a research focus for each big pharmaceutical company because of lots of patients with depression and long treatment cycle. But the innovation of new chemistry entities development is more and more difficult and the generics industry is growing prosperity. China is a big country of generics and China’s pharmaceutical enterprises will pay attention to generics of antidepressant drugs."Drug Registration Regulation " changes is bound to accelerate the generics listed, But patent protection for drugs have become more and more strict, and pharmaceutical enterprises may face more patent lawsuits.In view of this, domestic and foreign development status of antidepressants are studied by using the literature induction and comparative study; patent statistical and content are analyzed with the State Intellectual Property Office patent retrieval and service system, the European Patent Office, American food and Drug Administration orange book providing the data as the foundation, the general understanding of the application for Chinese patents of antidepressant drugs, and through in-depth study of patent information and patent protection strategy for global best-selling and new launched drugs of antidepressant. This paper outlines the related concepts and methods of patent analysis, and then the patent drugs were analyzed, and the global best seller and new antidepressant drug patent document information content analysis, on this basis, analysis of antidepressant drug patent protection strategy, finally attempts to seek the technical and legal information from patent information to provide our pharmaceutical enterprises the reference of antidepressant drug development and management.The statistical results of patent display that antidepressant drugs in China have1917patent applications in nearly20years, domestic applicants are superior in numbers, and this indicates that China has begun to pay attention to the R&D of antidepressants, but research is carried on by Company, University&Research situation and Individual. In order to improve the patent achievements transformation rate, Company should strengthen cooperation with Universities,&Research situation and Individual.Content analysis results show that branded companies apply salt, polymorphs, solvates, metabolites patents around the compound and process patent, controlled release new dosage, use patent about peripheral patents to extend product patent protection period. But at the same time, by focusing on the Chinese patent family and legal status, I found that some patent fails to apply for protection in our country, or the existing patent rights have been terminated because of various reasons. So generic companies can use technology information of the invalid patents freely and accelerate the generic drug.Patent strategy research results show that the successful developed drug often through building patent protection network around the compound molecular configuration for the basic patent, and through the application of peripheral patent to stop generic listed. Generic companies should pay attention to drug patent protection network earlier to detect patent network vulnerabilitie (?)d weave their own patent network to share the market.